Published ahead of print on April 25, 2008, doi:10.1165/rcmb.2008-0117TR
© 2008 American Thoracic Society DOI: 10.1165/rcmb.2008-0117TR
Cigarette Smoke Triggers Code Redp21CIP1/WAF1/SDI1 Switches on Danger Responses in the Lung1 Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, Program in Translational Lung Research, and 2 Department of Pathology, University of Colorado Denver, School of Medicine, Denver, Colorado Correspondence and requests for reprints should be addressed to Rubin M. Tuder, M.D., Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Denver, School of Medicine, 4200 East 9th Avenue, Campus Box C272, Denver, CO 80262. E-mail: Rubin.Tuder{at}UCHSC.EDU
The article by Yao and coworkers in this issue (Am. J. Respir. Cell Mol. Biol. 2008;39:7–18) reveals that the cyclin-dependent kinase inhibitor p21CIP1/WAF1/SDI1 (designated hereafter as p21), which has been linked to cell cycle growth arrest due to stress or danger cell responses, may modulate alveolar inflammation and alveolar destruction, and thus enlightens our present understanding of how the lung senses injury due to cigarette smoke and integrates these responses with those that activate inflammatory pathways potentially harmful to the lung (1). Furthermore, the interplay of p21 and cellular processes involving cell senescence and the imbalance of cell proliferation/apoptosis may provide us with a more logical explanation of how p21, acting as a sensor of cellular stress, might have such potent and wide roles in lung responses triggered by cigarette smoke. Molecular switches, ontologically designed for the protection of the host, are now hijacked by injurious stresses (such as cigarette smoke), leading to organ damage.
A paradigm is essential to the scientific inquiry. (2) No natural history can be interpreted in the absence of at least some implicit body of intertwined theoretical and methodological belief that permits selection, evaluation, and criticism. (3) Fundamental research discoveries inevitably drive conceptual shifts that bring us closer to scientific truths. In medicine, this effort translates into better health and living standards. However, as in most if not all branches of human knowledge, these discoveries carry a price. Traditional conceptual frameworks or paradigms cannot always explain newly generated knowledge obtained by experimentation and careful interpretation of scientific data. What once was new and revolutionary now becomes outdated and needs to be readdressed within a new conceptual framework. In fact, the past and the inevitable future clash and, from this dialectic (i.e., conflict of opposites), a new understanding emerges.
The article by Yao and coworkers in this issue of the AJRCMB (pp. 7–18), while exploring well-established paradigms of cigarette smoke–induced lung injury, provides data that support a potential conceptual shift regarding how the lung is damaged by persistent exposure to cigarette smoke (1). This paradigm has evolved based on the resemblance between emphysema and aging lung processes (4), the impact of lung injuries promoted by lifelong exposure to cigarette smoke, and the potential for an autoimmune component of inflammation in advanced stages of the disease (5). The inflammation and protease–antiprotease hypothesis of chronic obstructive lung disease represents the traditional paradigm or the status quo that aligns linearly cigarette smoke and inflammation (6). This hypothesis can be dated to the identification of The work by Yao and colleagues reveals that the cyclin-dependent kinase inhibitor p21CIP1/WAF1/SDI1 (designated hereafter as p21), which has been linked to cell cycle growth arrest due to stress or "danger" cell responses, may modulate alveolar inflammation and alveolar destruction, and thus enlightens our present understanding of how the lung "senses" injury due to cigarette smoke and integrates these responses with those that activate inflammatory pathways potentially harmful to the lung (Figure 1). Furthermore, the interplay of p21 and cellular processes involving cell senescence and the imbalance of cell proliferation/apoptosis may provide us with a more logical explanation of how p21, acting as a sensor of cellular stress, might have such potent and wide roles in lung responses triggered by cigarette smoke. Molecular switches, ontologically designed for the protection of the host, are now "hijacked" by injurious stresses (such as cigarette smoke), leading to organ damage. This concept, which is shared with the underlying processes that lead to aging, may also apply to several diseases, including COPD (18). It is apparent that a novel paradigm is emerging. This paradigm requires that we consider how cigarette smoke alters the molecular controls of lung cell homeostasis, leading to disruption of alveolar maintenance (19), with the destructive consequences of failure to repair and terminal senescence. These pathobiological processes may provide an alternative or be complementary to the models of unopposed apoptosis and extracellular matrix destruction.
Elucidation of the molecular regulation of cell cycle progression has proven to be central to our understanding of the most fundamental processes in living cells. Critical processes of post-replicative cell differentiation, proliferation and repair, neoplastic transformation, cell senescence, and apoptosis, among others, are integrated by molecules directly involved in activating or repressing different stages of cell cycle. Cell cycle progression to the S phase is regulated by complexes of cyclins and cyclin-dependent kinases (Cdks) (20). p21 acting as a central downstream target of p53 activation inhibits the cyclin E-CDK2 and cyclin D1-CDK4 complexes, and therefore can induce G1 arrest and block entry into the S phase of the cell cycle (21). Other family members in the Cip/Kip group of Cdk inhibitors include p27Kip1 and p57Kip2, which share significant sequence homology but have different cyclin-CDK targets (22). In the cytoplasm, p21 remains in quaternary complexes with cyclin and Cdks (23). p21 also interacts with proliferating cell nuclear antigen (PCNA), an accessory protein of DNA polymerase, and thereby inhibits DNA synthesis (24). The p21 gene is located at 6p21.2. Gene expression of p21 is activated by p53, growth factors including transforming growth factor β (TGF-β), cytokines, retinoids, along with many other factors, including the transcription factors Sp1/Sp3, Smads, Ap2, STAT, BRCA1, E2F-1/E2F-3, and CAAT/enhancer binding proteins a and h (25). c-Myc and c-jun both inhibit p21 expression (25). The biological actions of p21 are determined by its expression levels, affected by transcriptional factor regulation of the p21 promoter, transcript stability, and post-translational controls (25).
DNA damage triggers a "danger response" coordinated by the ataxia telengectasia mutated gene (ATM) and p53. This physiological and temporary response, as seen in
p21 is both necessary and sufficient to trigger replicative senescence (26). p21 knockout mice are generally healthy without organ system disease (28). Knockout mice do, however, develop spontaneous tumorigenesis, when followed out to an average age of 16 months (29). Mice deficient in the enzyme telomerase, which accounts for telomere repair and elongation of the end of chromosomes, have progressive and premature telomere shortening over generation crosses, particularly in highly replicative and stem cell–rich organs, including testis and the hematopoietic system. p21 is necessary in these mice to induce cell cycle arrest, as knocking out p21 in the telomerase-deficient mice prolongs lifespan with enhanced preservation of stem cells (30). p21 is also sufficient, as cells that are forced to overexpress p21 become arrested in G1 by the increased association of p21 with PCNA, cyclin D1, and Cdk4 (31). p21 is therefore not only required for regulation of the cell cycle in fully mature cells but also affects the outcome of stem cells in circumstances of stresses that may lead to their exhaustion, premature senescence, or aging (32). The central tenets of the concept of aging and activation of molecular switches involved in "danger" signals have been recently documented in cigarette smoke–induced emphysema. Emphysematous lungs exposed to cigarette smoke express the hypoxia-inducible, oxidative stress modulatory molecule RTP-801 (18). Human emphysematous lungs also have decreased telomere length, enhanced expression of p21, p16Ink4a, p19Arf, and the cytochemical marker of cellular senescence reliant on low pH-activated β-galactosidase activity (33). Furthermore, these results are complemented by evidence that these alterations are systemic since peripheral blood mononuclear cells share the telomere shortening seen in the lung (34) and alveolar macrophages from smokers have increased expression of p21 (35). The links among cell senescence, aging, and predisposition to cigarette smoke–induced emphysema were strengthened by the documentation that prematurely aged mice lacking the anti-aging protein senescence marker protein (SMP)-30 have increased alveolar injury and emphysema caused by cigarette smoke (36). This paradigm may not be restricted to cigarette smoke as recent reports have linked mutations in telomerase and the RNA component of telomerase (TERC) to interstitial lung disease, also shown to be associated with cigarette smoke (37). These data indicate that biological processes involved in aging, particularly oxidative stress, may hold the key to the unrelenting progression of COPD despite smoking cessation. Ceramide, which is increased in lungs of smokers and in mice exposed to cigarette smoke and mediates experimental emphysema (38), has been also shown to cause senescence (39) and promote a feedforward amplification of its pro-oxidative stress and apoptotic actions in vitro (40). It is tempting to interpret that the pathogenic role of p21 in mice exposed to cigarette smoke may be related to its pro-senescence properties, as suggested by Yao and coworkers (1). The paradigm centered on the role of p21 in senescence reveals facets neither predicted nor investigated by the proponents of the inflammation/protease–antiprotease hypothesis. Senescent cells are more prone to produce cytokines and therefore promote inflammation in vitro (41) and in vivo in late generation mice lacking TERC (26). Mice lacking p21 had markedly reduced lung inflammatory responses caused not only by acute (i.e., 3 d) cigarette smoke, but also lipopolysaccharide (LPS) inhalation (i.e., 24 h), and N-formyl-methionyl-leucyl-phenylalanine (fMLP) administration (i.e., 3 wk). These time frames are too short to postulate that cell senescence alone might have accounted for the injurious roles of p21. An alternative explanation for the observed protection in p21 knockout mice is that p21 drives macrophage maturation and differentiation. p21 knockout mice have decreased macrophage recruitment to atherosclerotic plaques and cytokine expression (42), findings that parallel those of Yao and colleagues (1) in the lung. In elegant studies, Ofulue and Ko showed that macrophages are required for cigarette smoke–induced emphysema in rodents exposed to cigarette smoke (10). Moreover, as p21-deficient macrophages can engulf more efficiently apoptotic cells than wild-type cells, it is possible that the protection seen in p21 knockout mice could be accounted for by the more efficient removal of apoptotic cells triggered by cigarette smoke or LPS inhalation (43).
Mice lacking p21 show remarkably decreased NF- B and inflammatory cytokine responses due to cigarette smoke, LPS, or fMLP when compared with wild-type mice (1). Since Yao and coworkers exposed mice to cigarette smoke for just 3 days, it is unclear whether these acute responses would predict or be relevant to long-term outcomes, since cigarette smoke produces mild emphysema in mice after 6 months of exposure to cigarette smoke. Although this potential caveat has not been elucidated thus far, the documentation that acute exposures to cigarette smoke lead to presence of elastin degradation products in bronchoalveolar lavage and alveolar inflammation support the potential relevance of the experimental approach taken by Yao and colleagues (44).
Yao and coworkers expand the scope of their investigation by using inhaled LPS or fMLP. Although LPS is often used to induce acute lung injury, long-term LPS treatment can mimic the COPD phenotype (45), while short-term LPS exposure has shown to induce bronchial epithelial cell apoptosis (46). LPS-induced inflammation is different from cigarette smoke–induced inflammation in that it does not involve metalloprotease-12 activity (47). fMLP, a bacterial peptide that functions as a chemoattractant for phagocytes, induces a full-scale neutrophil response including production of reactive oxygen species, granule enzyme release, and activation of various downstream signaling pathways, including those involving phophoplipase A and D, phosphotidylinositol 3-(PI3) kinase (PI3Kinase), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK). Consistent with its relevance in cigarette smoke–induced lung disease, the fMLP receptor is increased in neutrophils of patients with emphysema and in smokers (48). Both LPS and fMLP might cause alveolar destruction by enhancing neutrophil recruitment to the lung via the action of the collagen-derived peptide N-acetyl proline-glycin-proline (PGP). Degradation of the extracellular matrix generates PGP, which could therefore activate the CXCR2 receptor. This receptor is activated by ELR motif-CXC chemokines (IL-8, GRO- How does p21 regulate an otherwise classical inflammatory pathway? Among all agents of lung stress and injury triggered by cigarette smoke, oxidative stress is a leading and unifying agent of emphysema (51). Not only is cigarette smoke a major source of oxidants, but infiltrating inflammatory cells and alveolar cell apoptosis themselves generate potent free radicals (52). Furthermore, oxidative stress leads to enhanced inflammation (51), apoptosis (52), and potentially senescence via the p53/p21 pathway (41). Cigarette smoke damages DNA (53), which could activate a p53/p21 stress response as suggested by the co-expression of p53 and p21 in alveolar macrophages of smokers (35). The data of Yao and colleagues suggest that p21 enhances oxidative damage, as they demonstrate that p21 knockout mice have decreased levels of superoxide and hydroperoxides in cells retrieved by bronchoalveolar lavage or in lung tissue lysates. These findings are in agreement with data that forced in vitro expression of p21, but not the cell cycle inhibitor p16, triggers enhanced oxidative stress, which conversely up-regulates p21 expression (54).
Although it is unclear how p21 modulates oxidative stress, the authors suggest that p21-dependent kinase (PAK) links p21 with the activation of cytokines and NF-
Inflammation by LPS is mediated by binding to the complex LPS-binding protein (LBP)/CD14/TLR4 and activation of PAK in macrophages and monocytes, leading to release of inflammatory cytokines (TNF-
The novelty of the findings of Yao and colleagues lends itself to potential translational implications of manipulations of p21 levels and/or activity in cigarette smoke–induced lung injury, particularly of emphysema. As aforementioned, there are no therapies for the manifestations of chronic bronchitis and emphysema in chronic obstructive pulmonary disease. Their work is clearly relevant, since there is compelling evidence that smokers have increased expression of p21 and that cigarette smoke induces p21 expression in vitro and in experimental animals (35). Evidence that inhibition of p21 in wild-type mice exposed to cigarette smoke prevents or attenuates lung injury by cigarette smoke would have strengthened significantly the impact of the study by Yao and coworkers. Notwithstanding the advantages afforded by the availability of knockout mice, there is the risk that their attenuated responses to cigarette smoke (and LPS or fMLP) might have been shaped by compensatory mechanisms developed throughout their lifetime. Furthermore, a central question that remains unanswered is which lung cells mediate the p21 effects. Given that lung parenchymal and inflammatory cells have distinct but synergistic interactions throughout lung injury by cigarette smoke, these data are critical for the design of cell-specific treatment strategies. As in most centrally placed signaling molecules, there is a "biological price" to pay if these molecules are blocked or overexpressed. p21 plays a central role in stem cell maintenance, particularly during situations of stress. Too much or too little p21 leads to a decreased stem cell pool or stem cell exhaustion, respectively (26). The role of p21 remains ambiguous as some reports have described either worse or improved phenotypes in p21 knockout mice. In line with this potential discrepancy, we have observed that p21 knockout newborn mice showed significant lung damage to hyperoxia, including alveolar enlargement and evidence of alveolar cell apoptosis, when compared with wild-type pups (61). The work by Yao and colleagues, the human data regarding expression markers of cell senescence both in the lung and systemically, and the observation of emphysema in accelerated senescence models offer a novel perspective on the pathogenesis and progression of alveolar destruction due to cigarette smoke. Modulation of central pathobiological processes, such as oxidative stress, which intersect through relevant lung injury processes, including inflammation, apoptosis, and aging, remain an ideal target for therapies, with a potential application to those individuals predisposed to develop the disease as well as patients with advanced disease. However, as we learn of upstream "triggering" mechanisms involved in alveolar injury by cigarette smoke, such as p21, stage- and disease-specific therapies can be designed, particularly addressing earlier stages of the disease before overwhelming destruction, allied to progressive refinement of genetic markers of disease (62).
This work was supported by National Institutes of Health HL66554 and Alpha 1 Foundation research grants (to R.M.T.). Originally Published in Press as DOI: 10.1165/rcmb.2008-0117TR on May 5, 2008 Conflict of Interest Statement: R.M.T. received an unrestricted postdoctoral support grant from Quark Biotech for studies involving RTP801 in cigarette smoke–induced emphysema; $2,500 for speaker fees in a international conference sponsored by Astra Zeneca; and $1,500 from the Rush Medical Center's CME speakers training workshop titled "Simply Speaking PAH: An Expert Educators CME Lecture Series." None of the other authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Received in original form March 25, 2008
Related articles in AJRCMB:
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||